The profit recovery trend is clear, and the long-term value release of Jinhai Medical Technology (02225) can be expected

The Zhitong Finance App learned that recently, Jinhai Medical Technology (02225) disclosed its 2026 interim results and handed over an interesting phased questionnaire.

Judging from the operating results, the pace of the company's revenue expansion has accelerated, and the quality of profit has improved simultaneously. In the first half of 2026, the Group achieved revenue of SGD 34.21 million, a sharp increase of 134.16% over the previous year, showing strong sales growth momentum; losses attributable to shareholders during the same period were reduced to SGD 4.362 million, a decrease of 57.46% compared with the same period last year. Losses have narrowed drastically, mainly due to explosive growth in medical device-related businesses.

In the first half of 2026, the company's revenue structure was significantly optimized, and the strategic focus has successfully shifted from traditional labor services to a high-value-added medical device circuit. The share of revenue from minimally invasive surgical solutions, medical products and related service fees has climbed to 74.73%, making it a well-deserved new revenue pillar. Following a good increase in medical device sales revenue in 2025, the business's revenue surged 301.5% year-on-year in the first half of 2026 to reach SG$25.427 million, with sufficient momentum for sustainable growth.

At the same time, the company has also made substantial progress in cost control and debt optimization. Administrative expenses fell from 12.5 million Singapore dollars in the same period last year to 10 million, mainly due to a reduction in equity payments. As of June 30, 2026, the Group's cash and equivalents were 18.2 million, and the debt was 14.2 million, a steady decline from the end of 2025; the balance ratio fell to 25.5% from 28.7% at the end of 2025, and the capital structure continued to be optimized, providing a sufficient margin of safety for subsequent R&D and market expansion.

Behind the increase in performance is the company's long-term deep cultivation and continuous breakthroughs in the field of technology research and development. According to information, Jinhai Medical Technology's product matrix has covered a series of innovative products such as 4K ultra-high definition endoscopy systems, 3D and naked eye 3D image processing systems, 4K fluorescence and multi-spectral ultra-high definition endoscopy systems, and 8K endoscopy systems, and extended to supporting auxiliary equipment, forming a closed loop in the entire industry chain from R&D, production to sales and service.

From an industry perspective, the upgrading of China's medical system, the increase in residents' health consumption levels, and the popularization of the concept of early cancer screening continue to drive the rigid demand for minimally invasive diagnosis and treatment. Traditional open surgery is accelerating the shift to minimally invasive procedures. Stock replacement and incremental release space brought about by this structural change provided a broad stage for the company's medium- to long-term growth.

In order to further match the business expansion related to minimally invasive treatments, the company appointed Mr. Ma Chengdong as the chief marketing officer in August of this year. He has held key positions such as sales director and senior marketing and operation director in Greater China at multinational companies such as General Electric Healthcare and Medtronic, and has both a clinical medical background and nearly 30 years of practical marketing experience. Joining this time is expected to bring the company systematic marketing capabilities and mature channel management experience, and accelerate subsequent commercial expansion.

Overall, the explosive growth of the minimally invasive surgery solutions business has verified the company's solid skills in product development and manufacturing; the introduction of senior marketing talents indicates that the company is strengthening its commercialization capabilities at an accelerated pace.

Looking ahead to the second half of 2026 and beyond, Jinhai Medical is expected to occupy a more favorable competitive position in the import substitution process for domestic high-end equipment if it continues to seize the industrial opportunities of increasing penetration of minimally invasive surgery in China and the Asia-Pacific region while effectively responding to industry competition and policy variables.